

^{18}F -FLT PET for Visualization of Laryngeal Cancer: Comparison with ^{18}F -FDG PET

David C.P. Cobben, MD^{1,2}; Bernard F.A.M. van der Laan, MD, PhD³; Bram Maas, BSc¹; Willem Vaalburg, MSc, PhD¹; Albert J.H. Suurmeijer, MD, PhD⁴; Harald J. Hoekstra, MD, PhD²; Pieter L. Jager, MD, PhD¹; and Philip H. Elsinga, MSc, PhD¹

¹PET Center, Groningen University Hospital, Groningen, The Netherlands; ²Department of Surgical Oncology, Groningen University Hospital, Groningen, The Netherlands; ³Department of Otorhinolaryngology–Head and Neck Surgery, Groningen University Hospital, Groningen, The Netherlands; and ⁴Department of Pathology and Laboratory Medicine, Groningen University Hospital, Groningen, The Netherlands

The feasibility of ^{18}F -3'-fluoro-3'-deoxy-L-thymidine PET (FLT PET) for detecting laryngeal cancer was investigated and compared with ^{18}F -FDG PET. **Methods:** Eleven patients diagnosed with or strongly suspected of having recurrent laryngeal cancer and 10 patients with histologically proven primary laryngeal cancer underwent attenuation-corrected ^{18}F -FLT PET imaging 60 min after injection of a median of 213 MBq (range, 175–400 MBq) ^{18}F -FLT and attenuation-corrected ^{18}F -FDG PET imaging 90 min after injection of a median of 340 MBq (range, 165–650 MBq) ^{18}F -FDG. All patients were staged by endoscopy and CT according to the Union Internationale Contre la Cancer TNM staging system. All patients underwent biopsy of the laryngeal area after imaging. Lesions seen on ^{18}F -FDG PET and ^{18}F -FLT PET were compared with histopathologic results. Mean SUVs, maximum SUVs, and tumor-to-nontumor (TNT) ratios were calculated for ^{18}F -FLT and ^{18}F -FDG. Wilcoxon nonparametric testing was used for comparison of ^{18}F -FDG with ^{18}F -FLT uptake. The Spearman correlation coefficient was used to correlate mean SUVs, maximum SUVs, and TNT ratios of ^{18}F -FDG PET and ^{18}F -FLT PET. Two-tailed *P* values < 0.05 were considered significant. **Results:** ^{18}F -FDG PET and ^{18}F -FLT PET detected laryngeal cancer correctly in 15 of 17 patients. One lesion judged as positive on ^{18}F -FDG PET turned out to be normal tissue. Of 2 lesions judged as positive on ^{18}F -FLT PET, 1 turned out to be inflammation and the other to be normal tissue. Maximum SUVs were 3.3 (range, 1.9–8.5) for ^{18}F -FDG and 1.6 (range, 1.0–5.7) for ^{18}F -FLT (*P* < 0.001). Mean SUVs were 2.7 (range, 1.5–6.5) for ^{18}F -FDG and 1.2 (range, 0.8–3.8) for ^{18}F -FLT (*P* < 0.001). TNT was 1.9 (range, 1.3–4.7) for ^{18}F -FDG and 1.5 (range, 1.1–3.5) for ^{18}F -FLT (*P* < 0.05). **Conclusion:** The numbers of laryngeal cancers detected with ^{18}F -FLT PET and ^{18}F -FDG PET were equal. In laryngeal cancer, the uptake of ^{18}F -FDG is higher than that of ^{18}F -FLT.

Key Words: ^{18}F -FLT; ^{18}F -FDG; recurrent laryngeal cancer; primary laryngeal cancer; PET

J Nucl Med 2004; 45:226–231

The current standard for staging of laryngeal cancer is direct laryngoscopy complemented by histologic biopsy and CT or MRI (1,2). The detection of tumors and metastatic lymph nodes by CT and MRI is solely dependent on changes in tissue structure and size of lymph nodes (2). Therefore, nonenlarged metastatic nodes and primary or recurrent tumors that do not distort tissue structures can be missed. In addition, tissue changes caused by radiation therapy can also complicate the interpretation of CT and MR images. Despite the fact that biopsy is the gold standard, locating the possible site of recurrence for biopsy is still difficult, because most recurrent head and neck cancers are located in the submucosa (1). Moreover, the surgeon will be reluctant to obtain multiple blind biopsies, because these could initiate or aggravate radionecrosis (2).

^{18}F -FDG PET is accepted as a powerful, noninvasive metabolic imaging method for the diagnosis and staging of cancer (3–5). ^{18}F -FDG PET has been introduced as a noninvasive diagnostic tool in head and neck cancer, where it is especially accurate in detection and in providing prognostic information (6–8). However, experience with ^{18}F -FDG PET solely in patients with laryngeal cancer is limited. ^{18}F -FDG PET has proven in a few studies to be valuable in distinguishing between benign and malignant tissue changes after radiation therapy in patients with suspected recurrent laryngeal cancer (9–11). Even fewer data are available on ^{18}F -FDG PET in patients with untreated primary laryngeal cancer (9,12).

Because ^{18}F -FDG is also metabolized in nontumor tissue, results may be false-positive in inflammation, reactive tissue, or supraclavicular fat (13–15). In addition, muscle uptake of ^{18}F -FDG may interfere with PET interpretation. Moreover, the interval between radiation therapy and ^{18}F -FDG PET imaging is important for accurate diagnosis (1,9,16).

Recently, Shields et al. (17) introduced ^{18}F -3'-fluoro-3'-deoxy-L-thymidine (^{18}F -FLT) as a PET tracer that might not have these drawbacks (18). This pyrimidine analog is phos-

Received Jul. 9, 2003; revision accepted Sep. 22, 2003.
For correspondence or reprints contact: David C.P. Cobben, MD, PET Center, Groningen University Hospital, P.O. Box 30.001, Groningen, The Netherlands 9700 RB.
E-mail: D.C.P.Cobben@pet.azg.nl

phorylated by the enzyme thymidine kinase 1 (TK₁), which leads to intracellular trapping (17). During DNA synthesis, TK₁ activity increases almost tenfold and is thus an accurate reflection of cellular proliferation (19). ¹⁸F-FLT uptake is probably related to TK₁ activity and, therefore, also related to proliferation. The aim of this study was to investigate the feasibility of ¹⁸F-FLT PET in comparison with ¹⁸F-FDG PET for detection of primary and recurrent laryngeal cancer. A second aim was to investigate possible differences in uptake of ¹⁸F-FLT and ¹⁸F-FDG in malignant and normal tissue.

MATERIALS AND METHODS

Patients

This prospective study included 21 consecutive patients: 11 with suspected recurrent laryngeal cancer and 10 with primary laryngeal cancer. Informed consent was obtained. Patients were enrolled from September 2001 through March 2003.

The patients with suspected recurrent laryngeal cancer had been treated initially with radiation therapy for laryngeal squamous cell carcinoma. Recurrent disease was suspected in these patients, because increased hoarseness, edema, pain in the larynx, or referred pain developed. All patients with suspected recurrent laryngeal cancer underwent diagnostic laryngoscopy for biopsy. The patients with primary laryngeal squamous cell carcinoma were candidates for radiation therapy. The disease of all patients had been clinically staged according to the Union Internationale Contre la Cancer TNM classification (20).

All patients underwent physical examination of the head and neck, chest radiography, endoscopic examination under general anesthesia, biopsies of suspected areas, and spiral CT of the neck. For inclusion, liver and kidney functions and hematologic parameters (hemoglobin, hematocrit, erythrocytes, thrombocytes, leukocytes, and white cell count) had to be within normal limits. Pregnant patients and patients with psychiatric disorders were excluded. All screened patients were included in the study. The medical ethics committee of the Groningen University Hospital approved the study protocol.

Tracer Synthesis

Synthesis of ¹⁸F-FLT was performed according to the method of Machulla et al. (21). ¹⁸F-FLT was produced by ¹⁸F fluorination of the 4,4'-dimethoxytrityl-protected anhydrothymidine, followed by a deprotection step. After purification by reversed-phase high-performance liquid chromatography, the product was made isotonic and passed through a 0.22- μ m filter. ¹⁸F-FLT was produced with a radiochemical purity of >95% and specific activity of >10 TBq/mmol. The radiochemical yield was 7.5% \pm 5.1% (at end of bombardment).

Synthesis of ¹⁸F-FDG was performed according to the method of Hamacher et al. (22) by an automated synthesis module. The radiochemical yield was 65.9% \pm 7.1% (at end of bombardment).

PET Scanning

All studies were performed using an ECAT EXACT HR+ (Siemens/CTI Inc.). Before PET imaging, patients were instructed to fast for at least 6 h. They were also instructed to drink 1 L of water before imaging to stimulate ¹⁸F-FLT and ¹⁸F-FDG excretion from the renal calyces and subsequent voiding.

For injection of the radiopharmaceuticals, a venous cannula was inserted in each patient's forearm. The interval between the ¹⁸F-FDG PET and ¹⁸F-FLT PET imaging was a maximum of 16 d. All patients were scanned in 4 positions from the nose down in emission–transmission–transmission–emission mode, with 3 and 5 min per bed position for transmission and emission scanning, respectively. Twenty-one patients (20 men, 1 woman) with a median age of 65 y (range, 50–91 y) were included in this study (Table 1). Patients received a median of 340 MBq (range, 165–650 MBq) ¹⁸F-FDG and a median of 213 MBq (range, 175–400 MBq) ¹⁸F-FLT. Patients were scanned 60 min after ¹⁸F-FLT injection and 90 min after ¹⁸F-FDG injection. Previous experience with ¹⁸F-FLT indicated that tumor-to-nontumor (TNT) ratios were constant from 60 min after injection of the tracer. PET images were iteratively reconstructed (ordered-subset expectation maximization) (23).

Pathologic Evaluation

Biopsies of the laryngeal area and surgical specimens of total laryngectomies were examined on hematoxylin-and-eosin-stained sections. The pathologist was unaware of the results of the PET images. In patients in whom a total laryngectomy was performed, the maximum tumor diameter was obtained (Table 1). In the remaining patients only biopsies were performed, and these were used for histologic investigation.

Data Analysis

¹⁸F-FLT PET and ¹⁸F-FDG PET images were analyzed for uptake in malignant lesions and normal anatomic structures. A physician experienced with PET evaluated the images aware only of the location of the primary or suspected lesion and unaware of other clinical information.

¹⁸F-FLT PET and ¹⁸F-FDG PET images were first interpreted visually. The presence of a hypermetabolic lesion was judged as positive, and the absence of a hypermetabolic lesion was judged as negative. After visual interpretation, both the ¹⁸F-FLT PET and ¹⁸F-FDG PET images were analyzed randomly for hypo- and hypermetabolic lesions and sagittal sections. The slice with the highest uptake was selected for region-of-interest (ROI) analysis. After selecting the plane with the maximum SUV, an ROI was drawn manually. ROIs were placed at the 70% contour of the maximal SUV in the tumor when possible. In other cases, ROIs were drawn manually. The same ROI method was applied on the same slice in normal laryngeal tissue above or below the tumor site to calculate the background SUV. The mean SUV of the tumor was divided by the mean SUV of the background region to produce the TNT ratio. The TNT ratios and SUVs of ¹⁸F-FLT PET and ¹⁸F-FDG PET were compared. Images were displayed on a SUN workstation (Sun Microsystems). ROI calculation was performed using Clinical Applications Programming Package version 5 (CTI, Inc.).

Statistical Analysis

The results of the visually interpreted PET images were compared with the histologic data, which were used as standard. The Wilcoxon signed rank test was used to compare the mean SUVs, maximum SUVs, and TNT ratios of ¹⁸F-FDG PET and ¹⁸F-FLT PET. The Spearman correlation coefficient was used to correlate the mean SUVs, maximum SUVs, and TNTs of ¹⁸F-FDG PET and ¹⁸F-FLT PET. Two-tailed *P* values < 0.05 were considered significant.

TABLE 1
Patient Characteristics

Pt group	Pt no.	Sex	Age	TNM stage	PLC		Tx interval before		Pathology	¹⁸ F-FDG			¹⁸ F-FLT				
					Treatment status		PET scan	MDT (mm)		Max SUV tumor	Mean SUV tumor	TNT	Max SUV tumor	Mean SUV tumor	TNT		
Suspected recurrent laryngeal cancer																	
	1	F	52	T2N0	RTX		6 mo	NA	-	+	Inflammation	NA	NA	NA	1.4	1.1	1.1
	2	M	64	T1N0	RTX		9 y	NA	-	-	No abnormalities	NA	NA	NA	NA	NA	NA
	3	M	56	T3N2c	Follow-up [†]		3 mo	1.8	+	+	RLC	3.2	2.8	1.5	1.2	1.1	1.2
	4	M	70	T1a/CISN0	CO ₂ laser		6 y	NA*	+	+	RLC	1.9	1.5	1.5	1.5	1.2	1.5
	5	M	65	T2N0	RTX		9 mo	18	+	+	RLC	3.0	2.3	1.5	1.3	1.1	1.4
	6	M	50	T2N0	RTX		10 mo	15	+	+	RLC	8.5	6.5	4.1	2.9	1.9	3.2
	7	M	58	T1N0	RTX		1.5 mo	40	+	+	RLC	3.7	2.9	2.4	1.5	1.3	1.4
	8	M	66	T4N0	RTX		3 mo	20	+	+	RLC	3.3	2.6	1.4	1.9	1.4	1.4
	9	M	56	T3N1	RTX		16 mo	17	+	+	RLC	2.9	2.2	1.4	1.0	0.8	1.1
	10	M	65	T1aN0	CO ₂ laser		13 mo	NA	+	+	No abnormalities	1.9	1.6	1.3	1.5	1.2	1.1
	11	M	55	T2N0	RTX		5 mo	NA	-	-	Inflammation	NA	NA	NA	NA	NA	NA
Primary laryngeal cancer																	
	12	M	79	T2N0	RTX		NA	NA*	+	+	PLC	2.5	1.8	1.3	1.7	1.2	1.7
	13	M	72	T3-4N0	RTX		NA	NA*	+	+	PLC	5.8	4.4	3.1	5.7	3.8	3.5
	14	M	66	T1aN0	RTX		NA	NA*	-	-	PLC	NA	NA	NA	NA	NA	NA
	15	M	55	T2N0	RTX		NA	NA*	+	+	PLC	6.2	4.8	2.8	3.2	2.0	2.2
	16	M	65	T4N0	RTX		NA	NA*	+	+	PLC	5.8	4.4	2.3	3.7	2.6	2.2
	17	M	79	T4N0	RTX		NA	NA*	+	+	PLC	3.2	2.5	2.8	2.3	1.9	1.9
	18	M	64	T1aN0	RTX		NA	NA*	+	+	PLC	2.1	1.6	1.3	1.2	0.9	1.5
	19	M	72	T1bN0	RTX		NA	NA*	-	-	PLC	NA	NA	NA	NA	NA	NA
	20	M	53	T2N0	RTX		NA	NA*	+	+	PLC	3.8	2.8	4.7	1.6	1.2	2.0
	21	M	81	T2bN0	RTX		NA	NA*	+	+	PLC	4.6	3.5	2.9	1.6	1.1	1.6

*Only biopsies performed.

[†]Follow-up instead of RTX because of primary treatment of lung cancer.

PLC = primary laryngeal cancer; Tx interval = time interval between therapy of primary laryngeal cancer and PET scan; MDT = maximum diameter of the tumor; RTX = radiation therapy; NA = not applicable; - = negative; + = positive; RLC = recurrent laryngeal cancer.

RESULTS

Patients

Fifteen patients underwent biopsy of the laryngeal area after PET scans in the Groningen University Hospital. However, patients 7, 8, 11, 12, 15, and 20 underwent a biopsy in a referring hospital. These biopsies were performed at 7 mo and 17, 11, 27, 42, and 21 d, respectively, before the PET scans.

Visualization of Laryngeal Cancer

In patients 2, 11, 14, and 19, no uptake of ¹⁸F-FLT or ¹⁸F-FDG could be observed, and, therefore, no SUV could be calculated. Histopathologic investigation showed no malignancy in patients 2 and 11. However, in patients 14 and 19 histopathologic investigation showed 2 recurrent laryngeal cancers.

¹⁸F-FDG PET and ¹⁸F-FLT PET detected 15 of 17 laryngeal cancers. One lesion (in patient 10) judged as positive on ¹⁸F-FDG PET was found to be normal tissue. ¹⁸F-FLT PET and ¹⁸F-FDG PET missed 2 T1 tumors in patients 14 and 19. Two lesions (in patients 3 and 10) judged as positive

on ¹⁸F-FLT PET were found to be inflammation in one patient and normal tissue in the other. Figure 1 shows an ¹⁸F-FDG image and an ¹⁸F-FLT PET image of a patient with primary laryngeal cancer.

Comparison Between ¹⁸F-FDG and ¹⁸F-FLT Uptake

The uptake of ¹⁸F-FDG was significantly higher than that of ¹⁸F-FLT, whether expressed in mean SUV, maximum SUV, or TNT ratio (Table 2). The correlations between mean SUVs, maximum SUVs, and TNT ratios of ¹⁸F-FDG and ¹⁸F-FLT varied between 0.613 and 0.705 and were significant ($P < 0.05$).

DISCUSSION

This study was conducted on 21 patients and showed that both ¹⁸F-FDG PET and ¹⁸F-FLT PET could detect 15 of 17 laryngeal cancers. In 4 patients, lesions suggestive of laryngeal cancer turned out to be normal or inflammatory laryngeal tissue. ¹⁸F-FDG PET detected 1 of these lesions as positive, and ¹⁸F-FLT PET detected 2 of these lesions as positive. The uptake of ¹⁸F-FDG (mean SUV of 2.7 [range,




FIGURE 1. Coronal ^{18}F -FDG PET (A) and ^{18}F -FLT PET (B) images of patient 3, diagnosed with primary laryngeal cancer. With both imaging modalities, uptake of the tracer in the laryngeal region can be observed. Maximum ^{18}F -FDG SUV was 3.2, and maximum ^{18}F -FLT SUV was 1.2. Physiologic ^{18}F -FDG uptake can be seen in the muscles of the neck, and physiologic ^{18}F -FLT uptake can be seen in the bone marrow of the ribs and sternum.

1.5–6.5] in laryngeal cancer was significantly higher than that of ^{18}F -FLT (mean SUV of 1.2 [range, 0.8–3.8]).

Although few data are available, the limited ^{18}F -FDG PET data on sensitivity in this study are in the same range as ^{18}F -FDG PET data in the literature, where sensitivity for the detection of laryngeal cancer ranged from 80% to 97% (9,11,12,16,24,25) and specificity ranged from 61% to 82% (10,11,16). The specificity obtained in this study for ^{18}F -FDG PET (100%, 3 of 3) is less reliable and not comparable with the literature because of the low number of false-positive and true-negative lesions.

False-positive results with ^{18}F -FDG PET do occur, because ^{18}F -FDG is also trapped in normal tissue. Secretion of ^{18}F -FDG in normal mucosa and saliva and pooling of saliva in the larynx may cause increased uptake in the laryngeal area (13). Increased uptake is also found in salivary glands, tonsil tissue, muscle tissue of the larynx and the neck, benign laryngeal papilloma, and the base of the tongue (15). Moreover, wound healing after biopsy, local inflammation such as osteomyelitis or cellulitis, or a polyp may cause increased local ^{18}F -FDG uptake (9,10,13,26). Furthermore, the interval between radiation therapy and the ^{18}F -FDG PET is important for accurate diagnosis (9,10,16,27).

As an alternative to ^{18}F -FDG, tracers have been developed that are potentially more specific and that take part in other metabolic processes. Several amino acids that image protein synthesis have been developed as tracers. Most of these studies have been performed with L-[methyl- ^{11}C]-methionine (MET). The disadvantage of MET is substantial accumulation of non-protein-related metabolites in tumor

tissue (28). L-[1- ^{11}C]-tyrosine (TYR) also has been used to detect tumors and determine protein metabolism. In laryngeal and hypopharyngeal cancer, TYR was able to detect all primary tumors, with a correlation between protein synthesis rate and SUV (29–31). However, the disadvantage of this tracer is the low tumor uptake and accumulation in salivary glands, which could impair detection of metastatic lymph nodes in head and neck cancer (28,29). In 1998, Shields et al. (17) developed ^{18}F -FLT, a pyrimidine analog that indirectly measures DNA synthesis through the DNA salvage pathway. Recent articles about ^{18}F -FLT PET focused on the detection of colorectal and lung cancer and their metastases (32,33). A correlation was found between SUV and proliferation in single pulmonary nodules (32,34,35).

Despite the promising properties of ^{18}F -FLT, ^{18}F -FLT PET barely detected a recurrent laryngeal tumor (in patient 3) that displayed avid uptake of ^{18}F -FDG. The tumor was large (1.8 mm), poorly differentiated, and surrounded with ulcers. This could explain the low ^{18}F -FLT uptake and avid ^{18}F -FDG uptake in the surrounding inflammation. ^{18}F -FLT PET and ^{18}F -FDG PET missed 2 T1 tumors that were detected on CT. The size of these tumors could be below the detection level of PET, and a partial-volume effect could be involved. In the literature, ^{18}F -FDG PET has been reported to miss T1–T4 laryngeal tumors as well. However, no histologic explanation is given for these false-negative findings (11,24,25). Unfortunately, it is impossible to accurately quantify or assess the size of a primary laryngeal cancer. This is because diagnosis and extent of the tumor are obtained by a laryngoscopically guided biopsy and CT, because almost all T1–T3 tumors are treated with radiation therapy. The size of the biopsy obtained from the tumor is often too small to obtain reliable Ki-67 data for correlation with ^{18}F -FLT uptake. In contrast, it is possible to obtain reliable Ki-67 data in patients with T4 tumors, who undergo total laryngectomy and are not palliatively treated with radiation therapy. In these patients, the tumor can be fully examined histologically. However, a T4 tumor often causes acute respiratory distress leading to acute laryngectomy, making a PET scan unethical and impossible.

TABLE 2
Wilcoxon Nonparametric Test

	Max SUV* (range)	Mean SUV* (range)	TNT (range)
^{18}F -FDG PET	3.3 (1.9–8.5)*	2.7 (1.5–6.5)†	1.9 (1.3–4.7)‡
^{18}F -FLT PET	1.6 (1.0–5.7)	1.2 (0.8–3.8)	1.5 (1.1–3.5)

*SUV expressed as median (min–max).
† $P < 0.001$.
‡ $P < 0.05$.

Malignant tissue displayed a significantly higher uptake of ^{18}F -FDG than ^{18}F -FLT. The mean ^{18}F -FDG SUV reported in the literature for patients with primary or recurrent laryngeal cancer ranges from 4.6 to 10.7 (9,12,13). These values are higher than the maximum ^{18}F -FDG SUV of 3.3 (range, 1.9–8.5) and mean ^{18}F -FDG SUV 2.7 (range, 1.5–6.5) in this study. No literature is available on ^{18}F -FLT PET for detecting laryngeal cancer. However, the SUVs of ^{18}F -FDG PET and ^{18}F -FLT PET in patients with colorectal or lung cancer have been compared in the literature (32,33). The mean ^{18}F -FLT PET SUV in colorectal cancer was 4.2, compared with a mean ^{18}F -FDG PET SUV of 8.7. The ^{18}F -FLT SUV in lung cancer ranged from 1.2 to 3.1, and the ^{18}F -FDG PET SUV ranged from 1.7 to 8.9. Although these articles discuss different types of malignancies, they also reported significantly lower uptake of ^{18}F -FLT than ^{18}F -FDG, just as was found for the detection of laryngeal cancer in this study (32,33). The lower level of uptake probably raises the detection limit.

The correlation between ^{18}F -FDG and ^{18}F -FLT uptake was not strong. The SUV is the net result of several uptake processes. The availability of the tracer in the blood pool, nonspecific uptake, perfusion of the tumor, membrane transport, metabolic processes in which the tracer is involved, and (ir)reversible trapping of the tracer flow over the membrane are factors that can influence the SUV. It is our impression that both ^{18}F -FLT and ^{18}F -FDG are taken up by malignant cells but that the demand for glucose is larger than that for thymidine. The phosphorylation rate in vitro is about 30% of the phosphorylation rate of serum thymidine by TK₁, which could be an explanation for a low ^{18}F -FLT uptake in the tumor (36,37).

The number of patients in this study was too small to draw conclusions about the accuracy of ^{18}F -FDG PET and ^{18}F -FLT PET for detection of laryngeal cancer in general and for detection of primary or recurrent laryngeal cancer specifically. Larger groups of patients are needed with at least 2 observers to calculate the interobserver agreement to more accurately reflect clinical reality.

Future roles for ^{18}F -FDG PET and ^{18}F -FLT PET in laryngeal cancer are only partly clear. The role for ^{18}F -FDG PET in detecting laryngeal cancer seems to be in differentiating between tumor and nontumor tissue in patients with suspected recurrent laryngeal cancer (1,9–11,13). It is reasonable to delay biopsy on a negative ^{18}F -FDG PET assessment and prevent unnecessary biopsies that could initiate or aggravate radionecrosis (1,10,11). Imaging with PET lacks anatomic detail, but this could be overcome by the use of PET/CT. Too few data are available for the detection of primary laryngeal cancer untreated by radiation therapy (9,24,25). Further research is needed to investigate whether ^{18}F -FDG PET is an adequate tracer for the detection of primary laryngeal cancer. Because of the low uptake of ^{18}F -FLT, ^{18}F -FLT PET seems less adequate for the detection of laryngeal cancer (11).

The numbers of laryngeal cancers detected with ^{18}F -FLT PET and ^{18}F -FDG PET were equal. The uptake of ^{18}F -FDG in laryngeal cancer was higher than that of ^{18}F -FLT.

ACKNOWLEDGMENTS

This research was funded by the Dutch Cancer Foundation (grant 2000-2299).

REFERENCES

- Schechter NR, Gillenwater AM, Byers RM, et al. Can positron emission tomography improve the quality of care for head-and-neck cancer patients? *Int J Radiat Oncol Biol Phys.* 2001;51:4–9.
- Zinreich SJ. Imaging in laryngeal cancer: computed tomography, magnetic resonance imaging, positron emission tomography. *Otolaryngol Clin North Am.* 2002;35:971–991.
- Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. *Semin Nucl Med.* 2002;32:35–46.
- Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. *Lancet Oncol.* 2001;2:157–164.
- Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. *J Nucl Med.* 2001;42(suppl):1S–93S.
- Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. *J Clin Oncol.* 2002;20:4199–4208.
- Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. *J Clin Oncol.* 2002;20:1398–1404.
- Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET: a possible prognostic factor in head and neck cancer. *Br J Cancer.* 2002;86:512–516.
- McGuirt WF, Greven KM, Keyes JW Jr, et al. Positron emission tomography in the evaluation of laryngeal carcinoma. *Ann Otol Rhinol Laryngol.* 1995;104:274–278.
- Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. *Head Neck.* 2001;23:933–941.
- Greven KM, Williams DW III, Keyes JW Jr, McGuirt WF, Watson NE Jr, Case LD. Can positron emission tomography distinguish tumor recurrence from irradiation sequelae in patients treated for larynx cancer? *Cancer J Sci Am.* 1997;3:353–357.
- Lowe VJ, Kim H, Boyd JH, Eisenbeis JF, Dunphy FR, Fletcher JW. Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging. *Radiology.* 1999;212:799–802.
- Greven KM, Williams DW III, Keyes JW Jr, et al. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. *Int J Radiat Oncol Biol Phys.* 1994;29:841–845.
- Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular area fat (“USA-fat”): description on ^{18}F -FDG PET/CT. *J Nucl Med.* 2003;44:170–176.
- Stokkel MP, Bongers V, Hordijk GJ, van Rijk PP. FDG positron emission tomography in head and neck cancer: pitfall or pathology? *Clin Nucl Med.* 1999;24:950–954.
- Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. *Laryngoscope.* 2000;110:1493–1497.
- Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. *Nat Med.* 1998;4:1334–1336.
- Mier W, Haberkorn U, Eisenhut M. [(18)F]FLT: portrait of a proliferation marker. *Eur J Nucl Med.* 2002;29:165–169.
- Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. *J Biol Chem.* 1988;263:8350–8358.
- Sobin L, Wittekind C, eds. *TNM Classification of Malignant Tumors.* 6th ed. New York, NY: John Wiley & Sons; 2002.
- Machulla HJ, Blochler A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3'-deoxy-3'-[^{18}F]fluorothymidine ([^{18}F]FLT). *J Radiochem Nucl Chem.* 2000;243:843–846.
- Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[^{18}F] fluoro-2-deoxy-D-glucose using aminopolyether-supported nucleophilic substitution. *J Nucl Med.* 1986;27:235–238.

23. Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. *Eur J Nucl Med.* 1999;26:591–598.
24. Henze M, Mohammed A, Mier W, et al. Pretreatment evaluation of carcinomas of the hypopharynx and larynx with ^{18}F -fluorodeoxyglucose, ^{123}I -alpha-methyl-L-tyrosine and $^{99\text{m}}\text{Tc}$ - hexakis-2-methoxyisobutylisonitrile. *Eur J Nucl Med Mol Imaging.* 2002;29:324–330.
25. Kim HJ, Boyd J, Dunphy F, Lowe V. F-18 FDG PET scan after radiotherapy for early-stage larynx cancer. *Clin Nucl Med.* 1998;23:750–752.
26. Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. *Eur J Nucl Med.* 1998;25:1238–1243.
27. Bataini JP, Jaulerry C, Brunin F, Ponvert D, Ghossein NA. Significance and therapeutic implications of tumor regression following radiotherapy in patients treated for squamous cell carcinoma of the oropharynx and pharyngolarynx. *Head Neck.* 1990;12:41–49.
28. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. *J Nucl Med.* 2001;42:432–445.
29. de Boer JR, van der Laan BF, Pruim J, et al. Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas. *Eur J Nucl Med Mol Imaging.* 2002;29:1182–1187.
30. de Boer JR, Pruim J, Burlage F, et al. Therapy evaluation of laryngeal carcinomas by tyrosine-pet. *Head Neck.* 2003;25:634–644.
31. de Boer JR, Pruim J, van der Laan BF, et al. L-1- ^{11}C -tyrosine PET in patients with laryngeal carcinomas: comparison of standardized uptake value and protein synthesis rate. *J Nucl Med.* 2003;44:341–346.
32. Francis DL, Visvikis D, Costa DC, et al. Potential impact of $[(18)\text{F}]3'$ -deoxy- $3'$ -fluorothymidine versus $[(18)\text{F}]$ fluoro-2-deoxy- d-glucose in positron emission tomography for colorectal cancer. *Eur J Nucl Med Mol Imaging.* 2003; 30:988–994.
33. Yap C, Vranjesevic D, Cameron R, Czernin J. F18-fluorine-thymidine; a new molecular probe for PET imaging of cancer [abstract]. *Ann Surg Oncol.* 2003; 10:S38.
34. Buck AK, Schirmeister H, Hetzel M, et al. 3-deoxy-3- $[(18)\text{F}]$ fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. *Cancer Res.* 2002;62:3331–3334.
35. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3'-deoxy-3'- $[(18)\text{F}]$ fluorothymidine ($[(18)\text{F}]$ FLT) as a proliferation imaging tracer in humans: correlation of $[(18)\text{F}]$ FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. *Clin Cancer Res.* 2002;8:3315–3323.
36. Toyohara J, Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with ^3H thymidine and ^3H arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. *Nucl Med Biol.* 2002;29:281–287.
37. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. *J Biol Chem.* 1991;266:9032–9038.

